维格列汀在2型糖尿病治疗中的应用  

Viidagliptin treatment for type 2 diabetic patients in clinical practice

作　　者：王坚[1] 陈晔[1] 

机构地区：[1]南京军区南京总医院内分泌科,210002

出　　处：《中华内分泌代谢杂志》2011年第10期I0001-I0004,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：维格列汀是一种强效的特异性二肽基肽酶4抑制剂，通过抑制二肽基肽酶4对胰升糖素样肽1和葡萄糖依赖性促胰岛素分泌多肽的降解作用发挥效应。维格列汀为口服制剂，已经被批准治疗2型糖尿病。单药使用维格列汀或联合其他药物可以有效降低患者HbA，。水平。此外由于维格列汀降糖作用是血糖依赖性的所以低血糖发生率低，其不良反应如胃肠道反应和水肿发生率低，因此绝大多数患者对该药耐受良好。所以，维格列汀是2型糖尿病患者新的选择，良好的血糖控制可让患者减少远期并发症。Vildagliptin is a potent and specific inhibitor of dipeptidyl peptidase 4, which has been implicated to enhance and prolong the physiological actions of incretion hormones including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Vildagliptin is an orally administered drug and has been licensed for the treatment of type 2 diabetes mellitus. ~ildagliptin monotherapy or in combination with other drugs can effectively lower glycosylated haemoglobin levels to a great extent. In addition, vildagliptin acts in a glucose- dependent manner, explaining its low risk of hypoglycemia. This drug has been proved well tolerated with few gastrointestinal side effects or oedema. Therefore vildagliptin is a promising new option for type 2 diabetic patients, and these patients would achieve better glycemic control and fewer complications in the long run.

关 键 词：维格列汀 二肽基肽酶4 糖尿病 2型 

分 类 号：R587.1[医药卫生—内分泌]